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Keloids are benign skin tumors characterized by collagen accumulation and hyperproliferation of fibroblasts. To
find an effective therapy for keloids, we explored the pharmacological potential of ()-epigallocatechin-3-
gallate (EGCG), a widely investigated tumor-preventive agent. When applied to normal and keloid fibroblasts
(KFs) in vitro, proliferation and migration of KFs were more strongly suppressed by EGCG than normal fibroblast
proliferation and migration (IC50: 54.4 mM (keloid fibroblast (KF)) versus 63.0 mM (NF)). The level of Smad2/3, signal
transducer and activator of transcription-3 (STAT3), and p38 phosphorylation is more enhanced in KFs, and
EGCG inhibited phosphorylation of phosphatidylinositol-3-kinase (PI3K), extracellular signal-regulated protein
kinase 1/2 (ERK1/2), and STAT3 (Tyr705 and Ser727). To evaluate the contribution of these pathways to keloid
pathology, we treated KFs with specific inhibitors for PI3K, ERK1/2, or STAT3. Although a PI3K inhibitor
significantly suppressed proliferation, PI3K and MEK/ERK inhibitors had a minor effect on migration and
collagen production. However, a JAK2/STAT3 inhibitor and a STAT3 siRNA strongly suppressed proliferation,
migration, and collagen production by KFs. We also found that treatment with EGCG suppressed growth and
collagen production in the in vivo keloid model. This study demonstrates that EGCG suppresses the
pathological characteristics of keloids through inhibition of the STAT3-signaling pathway. We propose that
EGCG has potential in the treatment and prevention of keloids.
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INTRODUCTION
Keloids are benign cutaneous tumors, which extend beyond
wound margins (Rekha, 2004). Their pathology is distinguish-
able from that of normal skin by the substantial deposition of
collagen in the dermis, resulting in imbalanced production
and aggregation of the extracellular matrix (Marneros and
Krieg, 2004). Although there are no known cases of keloids
transforming into malignant tumors, they behave like benign
dermal fibroproliferative tumors, as they continue to grow
and extend beyond the confines of the original wound
margins and do not spontaneously regress (Ehrlich et al.,
1994). The difficulty in treating keloids is evidenced by the
large number of modalities of treatment (Al-Attar et al.,
2006). The most common therapeutic option for keloids are
intra-lesional injections of dexamethasone (Marneros and
Krieg, 2004; Rekha, 2004; Mutalik, 2005), but these
injections are often unsuccessful (Al-Attar et al., 2006).
There are several hypotheses as to the cause of keloid
formation, including altered growth-factor regulation, im-
mune dysfunction, aberrant collagen turnover, sebum or
sebocytes as self-antigens, and altered mechanics (Al-Attar
et al., 2006). No single unifying factor responsible for keloid
formation has been identified. Although the exact pathophy-
siology of keloid formation is unclear, previous studies have
focused on investigating abnormal increases in growth factors
and cytokines, such as transforming growth factor-a and
transforming growth factor-b, vascular endothelial growth
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Abbreviations: AKT, acutely transforming retrovirus AKT8 in rodent T-cell
lymphoma; EGCG, ()-epigallocatechin-3-gallate; ERK1/2, extracellular
signal-regulated protein kinase 1/2; FBS, fetal bovine serum; GSK, glycogen
synthase kinase; JNK, c-Jun NH2-terminal kinase; KF, keloid fibroblast; MAPK,
mitogen-activated protein kinase; NF, normal fibroblast; PBS, phosphate-
buffered saline; PI3K, phosphatidylinositol-3-kinase; siRNA, small interfering
RNA; Smad, Sma- and Mad-related proteins; STAT3, signal transducer and
activator of transcription-3; TUNEL, terminal deoxynucleotide transferase-
mediated dUTP nick-end labeling; VEGF, vascular endothelial growth factor
factor (VEGF), insulin growth factor, IL-6, and tumor-necrosis
factors, which are likely to alter the wound healing process
(Kelly, 2004). Although signaling by these growth factors and
cytokines is mediated by different receptors, they share
common intracellular effectors such as extracellular signal-
regulated protein kinase 1/2 (ERK1/2), p38 mitogen-activated
protein kinase (MAPK), Sma- and Mad-related proteins
(Smads), signal transducer and activator of transcription-3
(STAT3), and phosphatidylinositol-3-kinase (PI3K). For exam-
ple, TGF-b activates members of the Smad family, and TGF-b
expression is transcriptionally regulated by the p38, MEK/
ERK, and c-Jun NH2-terminal kinase (JNK) pathways
(Al-Attar et al., 2006; Wang et al., 2006; Xia et al., 2006).
Thus, many research groups have suggested modulation of
these signaling mediators to treat keloids. Many previous
studied demonstrated that suppression of Smad3, PI3K, ERK,
and STAT3 pathways is sufficient to inhibit extracellular matrix
production in keloids (Lim et al., 2003, 2006; Phan et al.,
2004; Wu et al., 2004; Zhang et al., 2004; Xia et al., 2006).
Green tea is one of the most widely consumed beverages
in Asia and represents a promising dietary source of
chemopreventive and chemoprotective phytochemicals
(Dreosti et al., 1997). Many epidemiological studies have
shown a protective effect of green tea against the develop-
ment of various types of cancers. Epigallocatechin-3-gallate
(EGCG) is one of the most abundant polyphenols present in
green tea (Kada et al., 1985). The chemopreventive and
selective antitumor effects of EGCG have been studied
extensively using animal carcinogenesis models as well as
several types of cultured cancer cell lines (Ahn et al., 1999;
Surh et al., 2001; DiPaola, 2002; Chen et al., 2003; Gupta
et al., 2003). EGCG has also been shown to modulate
multiple signal transduction pathways, including those
mediated by PI3K, MAPKs (ERK, p38 MAPK, and JNK),
STAT3, Smad2/3, and nuclear factor-kB, which all play
significant roles in tumorigenesis (Ahn et al., 1999; Surh
et al., 2001; DiPaola, 2002; Chen et al., 2003; Gupta et al.,
2003).
In this study, we tested the therapeutic potential of the
green tea polyphenol EGCG for treatment of keloids. Because
of the tumor-suppressive ability of EGCG, we postulated that
EGCG can reduce skin defects associated with keloids. We
found that EGCG treatment suppressed proliferation and
migration of normal and keloid fibroblasts (KFs) in vitro, but it
suppressed the proliferation and migration of KFs more than
that of normal fibroblasts (NFs). To determine the inhibitory
mechanism of EGCG, we compared the signaling responses
of NFs and KFs. We found that phosphorylation of Smad2/3,
STAT3, and p38 is enhanced in KFs, and the PI3K, MEK/ERK,
and STAT3 signaling pathways are inhibited by EGCG. Using
specific inhibitors and small interfering RNA (siRNA)
technique, we found that STAT3 is an important signaling
mediator for keloid pathology. Finally, we evaluated the
pharmacological potential of EGCG in vivo using a keloid
model. Treatment with EGCG suppressed growth and
collagen production of keloid nodules. Our findings suggest
that EGCG inhibits the pathological characteristics of
keloids by suppressing STAT3 signaling. We suggest that
EGCG has potential as a therapeutic and preventive agent
for keloids.
RESULTS
EGCG strongly inhibits KF proliferation
To explore the potential of EGCG as a keloid treatment agent,
we determined its effects on proliferation of normal and KFs.
Various doses of EGCG were administered to NFs and KFs in
culture and the effect on growth was determined by crystal
violet staining (Figure 1a and c). As previously described, KFs
grew faster than NFs (Nowak et al., 2000; Luo et al., 2001;
Lim et al., 2006). After 5 days in culture, KFs were almost
confluent, but continued to grow well past confluence.
However, proliferation of both NFs and KFs was reduced by
EGCG at doses of 25–100mM. Interestingly, proliferation of
KFs was more strongly suppressed by EGCG than was NF
proliferation (IC50, 54.4mM (KF) versus 63.0 mM (NF), on day
6). We also compared proliferation of NFs and KFs under
low-serum and low-cell density conditions to examine
whether EGCG suppressed abnormal growth of KFs. Under
low-serum (0.2%) conditions, KFs proliferated more rapidly
than NFs (Figure 1b). However, the enhanced proliferation of
KFs was completely inhibited by 25 mM EGCG. In addition,
under low-density culture conditions, KFs proliferated more
rapidly and generated larger colonies than NFs, but the
colony number of KFs was reduced by EGCG treatment
(Figure 1d). These results indicate that EGCG more strongly
inhibited proliferation of KFs than that of NFs under in vitro
culture conditions.
EGCG induces cell-cycle arrest rather than an exit from
the cell cycle in KFs
To determine the mechanism by which EGCG inhibits growth
of KFs, we analyzed apoptosis, replicative senescence, and
cell-cycle arrest in KFs in response to EGCG treatment. To
identify apoptotic cells, we performed a terminal deoxy-
nucleotide transferase-mediated dUTP nick-end labeling
(TUNEL) assay following EGCG treatment. As shown in
Figure 1e, EGCG treatment did not significantly alter the
percentage of TUNEL-positive cells 2 days later. Moreover,
the percentage of TUNEL-positive cells did not increase after 7
days of exposure to EGCG (data not shown). We examined
whether EGCG administration was correlated with accumula-
tion of cells possessing a sub-G1/S DNA content, as a measure
of apoptosis and necrosis, using flow cytometry. We found
that after 2 days of EGCG treatment, there was no consider-
able increase in sub-G1/S DNA content (Figure 1f; Figure S1a).
In contrast, treatment with the anticancer drug adriamycin
induced a large accumulation of cells possessing a sub-G1/S
DNA content (Figure 1f; Figure S1a). Furthermore, western
blot analysis demonstrated that levels of the proactive and
cleaved forms of PARP, caspase-3, and caspase-9, were not
affected by treatment with EGCG for 1 day (Figure S1b).
We also investigated whether EGCG induces replicative
senescence in KFs using senescence-associated b-galacto-
sidase staining. After 2 days of incubation with EGCG, the
percentage of senescence-associated b-galactosidase-positive
cells remained unchanged (data not shown). These results
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exclude the possibility that the growth-inhibitory mechanism
of EGCG was due to an increase in cells undergoing
apoptosis or replicative senescence. We also found that the
decline in cell proliferation in response to EGCG treatment
was reversible (Figure 1g). After incubation with 100 mM
EGCG for 3 days, KFs were cultured for an additional 4 days
with or without 100 mM EGCG and then analyzed as
described above. In untreated controls, the total number of
cells on day 7 was greater than the number of cells in the
EGCG-treated plates (Figure 1g). However, growth rate of
cells treated with EGCG for only the first 3 days recovered
after EGCG withdrawal (relative growth per day: untreated
cells, 0.391; 7-day treated cells, 0.175; 3-day treated cells,
0.236). Furthermore, it has been reported that EGCG below
100mM can cause apoptosis of various type of cancer cells
(Dreosti et al., 1997; Chen et al., 2003; Gupta et al., 2003;
Kumar et al., 2007). Altogether, this result indicates that the
suppressive effect of EGCG on KF proliferation was rever-
sible. Thus, EGCG strongly suppresses the growth of KFs even
though it induces a reversible cell-cycle arrest rather than a
permanent exit from the cell cycle.
EGCG suppresses wound healing-related processes
Fibroblast outgrowth, collagen overproduction, and abnor-
mal wound healing are major characteristics of keloid
pathology (Al-Attar et al., 2006). Proliferation and migration
of fibroblasts are involved in wound healing and, therefore,
expression of proliferation and migration-related proteins
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Figure 1. EGCG inhibits KF proliferation. (a) NFs and KFs were treated with different concentrations of EGCG for the indicated time periods. The cultures
were fixed, stained with a 0.01% crystal violet solution, and relative cell growth was determined as described under Materials and Methods. Data are expressed
as the mean±SE of three replicate experiments. (b) Serum-dependent inhibitory effects of EGCG. NFs and KFs were seeded and cultured in 10% FBS. After
6 hours, KFs were treated with different concentrations of EGCG in either high FBS (10%) or low FBS (0.2%) growth medium for 6 days. The cultures were fixed,
stained with 0.01% crystal violet solution, and relative cell growth was evaluated as described under Materials and Methods. Data are expressed as the
mean±SE of three replicate of each sample. (c) Representative micrographs of NFs and KFs after EGCG treatment for 7 days. Bars¼ 200mm. (d) Representative
micrographs of low-cell-density seeding assay cultures after 2 weeks of EGCG treatment. (e) Effect of EGCG on apoptosis in KFs measured by TUNEL. KFs were
treated with different concentrations of EGCG for 2 days and then labeled. TUNEL-negative cells were counted and the total number of viable cells was
expressed as a percentage of control cells. Data are expressed as the mean±SE of three replicate experiments. (f) KFs were seeded and cultured alone (control) or
in the presence of 100 mM EGCG for 2 days. After treatment, cells were labeled with propidium iodide for 30minutes. Labeled cells were analyzed by flow
cytometry. KFs treated with 1 mM adriamycin were used as positive control for apoptosis. (g) Growth inhibition of KFs by EGCG is reversible. KFs were
seeded and cultured in the presence or absence of 100 mM EGCG for 3 days, and then cultured for an additional 2–4 days with or without 100 mM EGCG.
Relative cell growth was evaluated as above. Data are expressed as the mean±SE of three replicate of each sample.
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may provide a useful index of therapeutic potential. In
addition, c-Myc and cyclin-D1, which are key components of
cell-cycle regulation, are overexpressed in, and regulate,
proliferation of keloids (Chen et al., 2004; Liu et al., 2004).
We, therefore, analyzed collagen type-I, c-Myc, and cyclin-
D1 expression in KFs following EGCG treatment. Exposure to
EGCG resulted in a dose-dependent decrease in collagen
type-I in mRNA(a1-chain) and protein level (Figure 2a).
Furthermore, we found that expression of c-Myc and cyclin-
D1 was also reduced at both transcriptional and translational
levels (Figure 2a).
We next determined whether EGCG inhibits migration of
KFs, which is an important process in wound healing. For
scratch-wound-closure assays, NFs and KFs were cultured to
confluence, wounded with a 200-ml pipette tip, as described
(Hu and Verkman, 2006), and treated with the indicated
concentrations of EGCG (Figure 2b). Untreated KFs closed
the wound within 24 hours, whereas NFs did not fully fill the
wounds (wound width: NF¼83.3±9.19, KF¼11.6±12.02).
However, EGCG strongly prevented wound closure of both
NFs and KFs. Even though migratory potential of both
NFs and KFs was suppressed by EGCG, their responses
differed depending on the dose of EGCG. Wounds of 50 mM
EGCG-treated KF cultures healed faster than those of NFs
(NF: 158.1±17.04, KF: 108.1±7.38), but the opposite trend
was observed in cultures treated with 100 mM EGCG (NF:
309.3±16.71, KF: 367.7±17.04). Thus, our results suggest
that EGCG suppresses the migratory potential of both normal
and KFs, but that this suppressive effect is greater in KFs.
Taken together, these findings indicate that EGCG efficiently
suppresses wound healing-related events, such as collagen
production, fibroblast outgrowth, and cell migration in KFs.
EGCG regulates the PI3K, MEK/ERK, and STAT3 pathways
in KFs
The above results prompted us to examine the molecular
mechanisms by which EGCG suppresses proliferation and
migration of KFs. Pervious researchers reported that activa-
tion of several intracellular signaling mediators, including
Smad3, ERK1/2, p38 MAPK, PI3K, and STAT3, plays a role in
the abnormal behavior of keloids (Tan et al., 1995; Chen
et al., 1999; Lim et al., 2003, 2006; Satish et al., 2004; Kuo
et al., 2005; Phan et al., 2005; Xia et al., 2006). We,
therefore, compared the phosphorylation level of these
signaling pathways in normal and KFs by western blotting
(Figure 3, and data not shown). Levels of phosphorylation of
acutely transforming retrovirus AKT8 in rodent T-cell
lymphoma (AKT), glycogen synthase kinase-3b (GSK-3b),
and b-catenin did not differ between untreated normal and
KFs. In contrast, phosphorylation level of Smad2/3, p38, and
STAT3 (Tyr705 and Ser727) was enhanced in KFs. Interest-
ingly, Smad2/3 was highly expressed in KFs, but Smad3 was
not detectable in NFs. Decreased phosphorylation of JNK was
observed in KFs. These results are consistent with the
enhanced expression of collagen type-I, c-Myc, and cyclin-
D1 in keloid pathology (Figure 2a), and demonstrate that
phosphorylation of Smad2/3, p38, and STAT3 is augmented
in KFs.
We further analyzed which signaling mediators were
regulated by EGCG in KFs. As shown in Figure 3a,
phosphorylation of Smad2 and Smad3 was not affected by
EGCG in KFs. Furthermore there were no remarkable changes
in Smad2/3 or Smad4 expression level following EGCG
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Figure 2. EGCG suppresses collagen production, cell proliferation specific
marker expression, and migration in KFs. (a) KFs were treated with various
concentrations of EGCG for 2 days. Total RNA was isolated and the
expression of collagen type-I a1-chain, cyclin-D1, c-Myc, was measured by
reverse transcription-PCR, with glycerladehyde-3-phosphate dehydrogenase
as a loading control. Proteins, obtained from the cell lysates and cell culture
supernatants (collagen type-I), were analyzed by western blot, with a-tubulin
as a loading control. (b) Representative micrographs of scratch-wound-closure
assays following EGCG treatment. NFs and KFs were synchronized for
2 hours, wounded, and treated with various concentrations of EGCG for
24 hours before being photographed. Each experiment was performed in
triplicate. Arrows indicate the mean±SE of three replicate of wound size
of each sample. Bars¼200 mm.
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treatment. However, phosphorylated MEK/ERK level was
significantly reduced within 1.5 hours of EGCG treatment
(Figure 3b). EGCG treatment did not affect JNK and p38
MAPK phosphorylation, but resulted in a significant, dose-
dependent reduction of phosphorylated AKT in both normal
and KFs (Figure 3c). Furthermore, phosphorylation of GSK-3b
and b-catenin, which are critical downstream elements of the
PI3K/AKT pathway, was also regulated by EGCG in a dose-
dependant manner (Figure 3c). The level of phosphorylated,
inactive form of GSK-3b was significantly reduced, whereas
that of the phosphorylated, degraded form of b-catenin
increased, concomitant with a slight decrease in total b-
catenin protein level in KFs. In addition, phosphorylation of
STAT3 decreased in response to EGCG treatment. Two STAT3
residues, Tyr705 and Ser727, were highly phosphorylated in
KFs, but levels of these phosphorylated forms of STAT3 were
diminished by EGCG in a dose-dependant manner. Together,
these results suggest that EGCG suppresses the PI3K, MEK/
ERK, and STAT3 pathways, and that this suppression is
correlated with proliferation and migration in KFs.
Collagen production is regulated by STAT3 signaling,
not PI3K or MEK/ERK signaling, in KFs
In view of the above results, we specifically examined the
roles of the PI3K, ERK, and STAT3 pathways in the expression
of collagen and cell-cycle regulators using specific inhibitors
for PI3K (LY294002), MEK (U0126), and JAK2/STAT3
(AG490). After synchronization in growth medium, KFs were
cultured in the presence of the indicated concentrations
of inhibitors for 1.5 hours or 2 days and protein extracts
were then prepared for western blot analysis. As shown in
Figure 4, 10 mM LY294002, 10 mM U0126, and 100mM AG490
completely inhibited AKT, ERK1/2, and Tyr705 STAT3
phosphorylation, respectively. Higher concentrations of
AG490 (200mM) showed acute toxicity and were not used
for these assays (data not shown). Treatment with 50–100 mM
EGCG resulted in significant reduction of phosphorylated
levels of AKT, ERK1/2, and STAT3 at Tyr705. As shown in
Figure 4a, c-Myc, cyclin-D1, and collagen expression was not
affected significantly by U0126 treatment. However, phos-
phorylation of GSK-3bwas suppressed by LY294002 treatment
and the total amount of b-catenin and its targets
c-Myc and cyclin-D1 decreased (Figure 4b). Interestingly,
neither LY294002 nor U0126 treatment affected production of
collagen (Figure 4a and b). In contrast to the PI3K and MEK
inhibitors, 100mM AG490 efficiently inhibited phosphorylation
of STAT3 at Tyr705, and significantly reduced collagen type-I
production, similar to EGCG. In addition, expression of STAT3
targets, such as Bcl-2, cyclin-D1, c-Myc, and anti-apoptotic
Bcl-xL, significantly decreased following AG490 and EGCG
treatment. These data collectively show that STAT3 is the
major pathway regulating collagen expression in KFs. Further-
more, neither the PI3K nor ERK1/2 pathways are required for
collagen production, even though the PI3K pathway is
involved in regulation of proliferation-related proteins in KFs.
STAT3 inhibition suppress proliferation and migration of KFs
We next tested whether inhibiting the PI3K, MEK/ERK, or
STAT3 pathways would directly suppress proliferation and
migration of KFs (Figure 5). When KFs were incubated with
LY294002, their growth was inhibited in a dose- and time-
dependent manner (Figure 5a, middle panel, IC50¼7.68 mM).
LY294002 at 10 mM suppressed proliferation at a rate similar
to that of 100 m EGCG. AG490 treatment also resulted in a
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Figure 3. EGCG regulates the PI3K, MEK/ERK, and STAT3 pathways in KFs. NFs and KFs were cultured for 1.5 hours in the presence or absence of the
indicated concentrations of EGCG. Total-cell lysates were prepared for western blotting. Blots were incubated with antibodies recognizing the total and
phosphorylated forms of components of the (a) Smad pathway (*, Smad2, **, Smad3), (b) MAPK pathways, (c) PI3K/AKT pathway; and (d) STAT3 pathway
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significant reduction of proliferation of KFs (Figure 5a, right
panel, IC50¼94.0 mM). However, U0126 did not suppress KF
proliferation, although 10mM U0126 completely inhibited
ERK1/2 phosphorylation (Figure 5a, left panel, and Figure 4a,
IC50¼27.7 mM). Together, these data indicate that the PI3K
and STAT3 pathways, but not the MEK/ERK pathway, are
involved in KF proliferation.
We further analyzed the effects of treatment with
combinations of specific inhibitors. Because the PI3K, MEK/
ERK, and STAT3 activities in KFs were all suppressed by
EGCG, we predicted that combining inhibitors would
recapitulate the effects observed following EGCG adminis-
tration. Prior to proliferation assays, we determined the
concentrations of LY294002, U0126, and AG490 required
for inhibiting phosphorylation of AKT, ERK, and STAT3 at
Tyr705 to extents similar to that with 100mM EGCG
treatment. As shown in Figure 4, treatment with 5 mM
LY294002, 5 mM U0126, or 100mM AG490 blocked AKT,
ERK1/2, and Tyr705 STAT3 phosphorylation, respectively, to
the same extent as with 100 mM EGCG. We then cultured KFs
with U0126 (5 mM), LY294002 (5mM), and AG490
(50–100 mM), alone or in combination. LY294003 inhibited
the growth of KFs, but not to the extent as that with 100 mM
EGCG treatment. In contrast, U0126 had no effect on cell
growth (Figure 5b). However, AG490 strongly suppressed the
growth of KFs as much as 100mM EGCG did. Furthermore,
combined treatment with AG490, LY294002, and U0126 did
not further suppress proliferation compared with treatment
with AG490 alone (Figure 5b).
Similar patterns were observed in the wound-closure assay
(Figure 5c). Neither LY294002 nor the LY294002/U0126
combination significantly suppressed migration. However,
incubation with AG490, alone or in combination with the
other inhibitors, strongly suppressed migration of KFs. These
findings suggest that EGCG blocks keloid pathology by
suppressing STAT3 and that the PI3K- and MEK/ERK-signaling
pathways, although inhibited by EGCG, do not play a critical
role in keloid pathology.
Proliferation and migration of KFs is inhibited by STAT3
siRNAs and cucurbitacin-I
To confirm the role of STAT3 in migration of KFs, fibroblasts
were transfected with siRNAs targeting STAT3 and wound-
closure assays were performed. Before wound-closure assays,
we verified STAT3 inhibition by western blotting. As shown
in Figure 6a, STAT3 siRNA-1 had the strongest suppressive
effect on STAT3 expression, although all STAT3 siRNAs
inhibited STAT3 expression to some degree. Interestingly,
siRNA suppression of STAT3 was highly correlated with
reduced expression of collagen type-I, c-Myc, and cyclin-D1.
Consistent with the western blotting results, STAT3 siRNA-1
significantly suppressed KF migration into scratch wounds,
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Figure 6. Effects of STAT3 siRNAs and cucurbitacin-I on proliferation and migration of KFs. (a) KFs were transfected with STAT3 siRNAs (siRNAs 1–3) and
GFP siRNA (negative control) and subsequently cultured 72hours. Total-cell lysates and cell culture supernatants (collagen type-I) were prepared for western
blotting and probed with antibodies recognizing STAT3, collagen type-I, c-Myc, cyclin-D1, and a-tubulin. (b) In vitro scratch-wound-closure assays with STAT3
siRNA- and GFP siRNA-transfected KFs. STAT3 siRNA- and GFP siRNA-transfected KFs were collected 48 hours after transfection and replated at confluent
densities. KFs were synchronized for 2 hours, wounded, and cultured in the presence or absence of EGCG for 24 hours before being photographed.
Each experiment was performed in triplicate. Arrows indicate the average size of wounds. Bars¼ 200mm. (c) KFs were co-transfected with STAT3
siRNAs-co-transfected and GFP siRNA-transfected and subsequently cultured 72 hours. Total-cell lysates were prepared for western blotting and probed
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EGCG. (f) In vitro scratch-wound-closure assays in KFs treated with cucurbitacin-I or EGCG. Bars¼ 200 mm.
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but green fluorescent (GFP) siRNA-transfected KFs healed the
wounds (Figure 6b). We further evaluate the effect of EGCG
in fibroblasts pretreated with the siRNA STAT3. For complete
inhibition of STAT3, we co-transfected all STAT3 siRNAs and
performed wound-closure assays. Co-transfection of siRNA
STAT3s almost completely blocks STAT3 protein expression
and strongly suppressed KF migration into scratch wounds
(Figure 6c and d). Upon EGCG treatment of siRNA-
transfected KFs, cell migration of STAT3 siRNA-co-trans-
fected KFs was not decreased significantly(Figure 6d). This
result implied that STAT3 inhibition might be the major
mechanism for suppression of KF migration by EGCG.
We also examined proliferation and migration of KFs
treated with cucurbitacin-I, known as another inhibitor
specific to JAK/STAT3 but not Ras, ERK1/2, or JNK pathways
(Blaskovich et al., 2003). Proliferation assays were performed
on cultures treated with 5 or 10 mM cucurbitacin-I. As shown
in Figure 6e, cucurbitacin-I treatments decreased prolifera-
tion of KFs, but not to the extent as observed with 100mM
EGCG treatment. In contrast, 10 mM cucurbitacin-I suppressed
cell migration more strongly than EGCG (Figure 6f). Together,
these data demonstrate that STAT3 is an important signal
mediator of proliferation and migration in KFs.
EGCG suppresses nodule development and collagen
production in an in vivo keloid model
To evaluate the therapeutic potential of EGCG in treatment of
keloids, we implanted normal and KFs into the backs of nude
mice and they were randomly grouped 7 days after
implantation and treated by intra-lesional injection with
1.25mg per nodule EGCG or phosphate-buffered saline
(PBS). At day 17, the size of KFs nodules was twice that of NF
nodules (Figure 7b). However, EGCG treatment markedly
reduced nodule size compared with that in untreated keloid
nodules. The average weight of keloid nodules was decreased
by EGCG treatment, and was similar to that of NF nodules
(Figure 7b). The average inhibition ratio of EGCG was 58%.
Histologically, cellularity of KF nodules were higher than that
of NF nodules (Figure 7c, upper panel). In addition, blood
vessels were well developed around the keloid nodules, but
not around NF nodules (Figure 7a). However, EGCG
treatment suppressed cellularity and blood vessel formation
around the keloid nodules. There was no significant change
in the weight and appearance of mice in any of the
experimental groups. We examined collagen production by
immunohistochemistry. As illustrated in Figure 7c, collagen
fibers were prominent in the nodules of KFs, but not in those
of NFs. However, collagen accumulation of keloid nodules
was repressed by EGCG treatment. Moreover, STAT3
phosphorylation at Tyr705 was also suppressed in EGCG-
treated keloid nodules (Figure 7c). These observations suggest
that EGCG inhibits keloid development and collagen
production by STAT3 suppression in an in vivo model.
DISCUSSION
Keloids are benign cutaneous tumors that develop after
dermal injury and exhibit vigorous and continuous produc-
tion of collagen (Rekha, 2004). Many groups have explored
the potential relationship between the abnormal expression
of growth factors and cytokines and cell migration (Phan
et al., 2004, 2005; Sato, 2006). TGF-b, platelet-derived
growth factor, epidermal growth factor, VEGF, connective
tissue growth factor, and IL-6 have all been reported to play
an important role in keloid pathology (Tan et al., 1995; Satish
et al., 2004; Khoo et al., 2006; Wu et al., 2006). These factors
accelerate migration by stimulating collagen production and
proliferation of KFs in vitro. Most growth factors and
cytokines transmit their signals through cognate receptors
linked to specific intracellular signaling pathways. Interest-
ingly, however, in keloid development, common intracellular
pathways are stimulated by a number of different growth
factors.
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Figure 7. EGCG suppresses growth and collagen production in an in vivo keloid model. (a) Representative photographs of NF and KF nodules embedded in the
panniculus muscle of nude mice. Mice were randomly grouped 7 days after implantation and treated by intra-lesional injection with 1.25mg per nodule EGCG
or vehicle (PBS). All animals were killed 17 days after implantation and keloid nodules were excised (NF, NF-derived nodules; KF, KF-derived nodules;
KF-EGCG, EGCG-treated nodules derived from KFs). (b) Representative photographs of NF and KF nodules excised from the panniculus muscle of nude
mice (upper panel) and average weight of excised nodules (lower panel). (c) Hematoxylin and eosin (H&E, upper panel), anti-human collagen (middle panel),
and p-Tyr705 STAT3 (lower panel) antibody staining of normal and KF nodules. Bars¼ 50 mm.
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EGCG, the most abundant polyphenol in green tea, shows
various pharmacological effects, including antitumor activity,
by regulating multiple signaling pathways, with a wide range
of health benefits. In skin tumors, topical treatment or oral
consumption of green tea polyphenols or EGCG inhibits
chemical carcinogen- or UV radiation-induced skin carcino-
genesis in different animal models (Luo et al., 2001; Al-Attar
et al., 2006). Furthermore, the apoptotic effects of EGCG are
highly selective for tumor cells, leaving normal tissues
undamaged (Ahn et al., 1999; Wang and Bachrach, 2002;
Paul et al., 2005). In addition, the safety of EGCG has been
demonstrated by many research groups (Kubota et al., 2002;
Ullmann et al., 2003; Kumar et al., 2007). Thus, EGCG has
been studied extensively as a potential treatment for various
types of tumors.
Here, we further explored the pharmacological potential
of EGCG in treatment of keloids using in vitro and in vivo
KF models. These models are useful as the abnormalities
observed in keloids, such as hyperproliferation and collagen
overproduction, are mostly mediated by KFs and can be
recapitulated. We demonstrated here that EGCG suppresses
proliferation and migration of NFs and KFs (Figures 1 and 2).
However, EGCG had a stronger effect on KFs, since EGCG’s
IC50 for proliferation was higher in NFs (NF: 63.0 mM versus
KF: 54.4mM, on day 7). In addition, EGCG inhibits KF
proliferation by cell-cycle arrest rather than inducing a
permanent exit from the cell cycle. These data imply that
EGCG suppresses keloid development without damaging
normal skin. These findings are consistent with a previous
report that EGCG suppresses adhesion-related signaling in
NFs, without cytotoxic or proapoptotic activity (Hung et al.,
2005).
Our results have also demonstrated that phosphorylation
of Smad2/3, p38, and STAT3 is greatly enhanced in KFs, but
phosphorylation of the AKT pathway components is similar to
that in NFs. These data imply that Smad2/3, p38, and STAT3
may be suitable therapeutic targets for keloids, as the
phosphorylation level of these signaling pathways differs
from that in normal tissue. EGCG inhibits one of these KF-
activated pathways, the STAT3 pathway.
The relationship between keloids and STAT3 activity was
recently demonstrated (Lim et al., 2006) by showing that
STAT3 contributes to keloid pathogenesis by promoting
collagen production, cell proliferation, and migration. This
report is consistent with our findings presented here. We
found that EGCG blocked STAT3 phosphorylation (Tyr705
and Ser727) and that inhibition of STAT3 by AG490, STAT3
siRNA, and cucurbitacin-I decreased collagen production,
proliferation, and migration of KFs. STAT3 is an oncogene
and a latent transcription factor that is involved in diverse
processes, including cell proliferation, migration, inflamma-
tion, immune responses, and cell survival. It is activated by
various growth factors and cytokines, including platelet-
derived growth factor, VEGF and IL-6, which have also been
linked to keloid pathology (Darnell, 1997). These reports and
our findings presented here suggest that EGCG suppresses
keloid development. EGCG is likely to regulate signaling
mediated by a number of soluble factors, since no single
unifying factor that is responsible for keloid formation has
been identified.
EGCG suppresses the PI3K, MEK/ERK, and STAT3 path-
ways in KFs. However, treatment with combinations of
inhibitors demonstrated that PI3K and MEK/ERK signaling did
not contribute to proliferation and migration, but the STAT3-
signaling pathway did (Figure 5b and c). Furthermore, EGCG
did not synergically suppress migration of STAT3 siRNA-co-
transfected KFs even though PI3K- and MEK/ERK-signaling
pathways were strongly suppressed by EGCG (Figure 6d).
This result is inconsistent with previous reports (Mirza et al.,
2000; Lorenzini et al., 2002; Lim et al., 2003), which
demonstrated that the PI3K and ERK1/2 pathways do play a
role in cell proliferation, survival, and collagen expression in
KFs. These differences may be the result of differences in the
signaling status of KFs due to different cell culture systems
and patient variations. For example, we cultured normal and
KFs in low-glucose DMEM medium with 10% fetal bovine
serum (FBS), because high glucose (hyperglycemic medium)
induces premature replicative senescence in NFs (Blazer
et al., 2002). In the low-glucose culture medium, we cultured
two patient-derived KFs for more than 30 passages, which is
three times longer than their previously reported lifespan in
culture (Yamamoto and Inoue, 1982).
Dexamethasone, which is the most common keloid
therapeutic agent, induces keloid regression through suppres-
sion of VEGF expression and KF proliferation (Wu et al.,
2006). Because EGCG inhibits VEGF expression in human
breast cancer cells (Masuda et al., 2002), we hypothesized
that EGCG and dexamethasone may suppress keloid’s
pathology through similar mechanisms. We observed pro-
liferation and migration of KFs following EGCG and
dexamethasone treatment (Figure S2). In our experimental
system, the KF proliferation rate after 7 days of dexametha-
sone treatment was reduced, but not to the extent as observed
after EGCG treatments of the same length. Furthermore,
dexamethasone did not significantly inhibit migration or alter
the morphology of KFs. We also investigated the effect of
EGCG and dexamethasone treatment on VEGF expression in
KFs (Figure S2c). Both EGCG and dexamethasone inhibited
VEGF expression at the mRNA level. Furthermore, we
observed that EGCG treatment suppressed blood vessel
formation around keloid nodules (Figure 7b). Taken together,
these results imply that EGCG could be a more effective
therapeutic agent for keloids than dexamethasone, even
though the two chemicals share a common target molecule,
VEGF.
To use EGCG as a therapeutic agent, optimal concentra-
tions and treatment methods should be determined. We used
a range of EGCG concentrations, from 25 to 100 mM, in the
in vitro studies and 1.25mg per nodule in the in vivo study. In
contrast, pharmacokinetic studies conducted on humans
indicate that the physiologically relevant serum concentra-
tions of EGCG may be in the high nanomolar range by daily
oral administration. Therefore, topical or intra-lesional
administration of EGCG may be a more effective option for
keloid therapy. A clinical study examining the ability of either
topical or oral administration of green tea extract products to
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reduce the appearance of photoaging skin (Chiu et al., 2005)
demonstrated that topical administration of EGCG more
effectively protected against UV-induced damage to the skin.
Furthermore, we observed that intra-lesional injections of
1.25mg per nodule (E62mgkg1) EGCG inhibited keloid
development without systemic health damage. In addition, it
had been reported that a dose of 200mg EGCG per kg
induced no toxicity (Kubota et al., 2002; Ullmann et al.,
2003; Isbrucker et al., 2006; Kumar et al., 2007).
In summary, we have demonstrated that EGCG suppresses
the pathological characteristics of KFs by inhibiting STAT3
signaling. Although EGCG inhibits PI3K and MEK/ERK
signaling, modulation of these pathways did not further
block proliferation, migration, or collagen production in KFs
treated with STAT3 inhibitors. Together, these results suggest
that EGCG could be used as a safe, alternative keloid
therapeutic agent.
MATERIALS AND METHODS
Reagents
U0126 was purchased from Promega (Madison, WI). LY294002,
EGCG, and a mouse anti-a-tubulin antibody were purchased from
Sigma-Aldrich (St Louis, MO). Rabbit anti-cyclin-D1 and rabbit anti-
c-Myc antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Rabbit anti-phospho-Thr180/Tyr182 p38 antibo-
dies were purchased from Abcam (Cambridge, UK). Rabbit anti-
phospho-MAPK 1/2 (ERK1/2), anti-phospho-Thr183/Tyr185-JNK,
and anti-phospho-Thr221/Thr223-JNK antibodies were purchased
from Upstate (Chicago, IL). Anti-AKT, anti-phospho-Ser473-AKT,
anti-GSK-3b, anti-phospho-Ser9-GSK-3b, anti-b-catenin, anti-phos-
pho-Ser33/37/Thr41-b-catenin, anti-phospho-Ser217/221-MEK 1/2,
anti-STAT3, anti-phospho-Tyr705-STAT3, anti-phospho-Ser727-
STAT3, anti-Smad2/3, anti-phospho-Smad2, anti-phospho-Smad3,
anti-Smad4, and anti-Bcl-xL antibodies were all rabbit polyclonal
antibodies and were obtained from Cell Signaling (Danvers, MA).
The mouse anti-collagen type-I antibody was purchased from R&D
Systems (Minneapolis, MN). Horseradish peroxidase-conjugated
goat anti-mouse and anti-rabbit secondary antibodies were pur-
chased from Zymed (South San Francisco, CA). The chemilumines-
cence detection system was from Pierce (Rockford, IL). Tissue
culture dishes, six-well plates, and 96-well plates were purchased
from Nunc (Naperville, IL).
U0126, LY294002, AG490, and cucurbitacin-I are MEK1/2-,
PI3K-, and JAK2/STAT3-specific inhibitors, respectively. They were
dissolved in DMSO (with final concentration not exceeding 0.1%)
and stored in a frozen condition, at 20 1C, away from light. The
final concentration of DMSO in experimental treatments never
exceeded 0.1%. Stock solutions of EGCG in DMEM (Hyclone,
Logan, UT) without FBS were stored at 70 1C.
Normal and KF culture
Primary normal and KF cultures were established as described
previously (Blazer et al., 2002; Lim et al., 2006). Normal (three
patients) and keloid (two patients) tissues obtained from patients
undergoing surgical excision were collected aseptically in a tube
containing low-glucose (1000mgml1) DMEM and antibiotics
(penicillin 100Uml1, streptomycin 100mgml1) (Gibco, Grand
Island, NY). Samples of dermis were washed twice with a PBS
containing antibiotics and were incubated in a solution of
collagenase type-I (0.5mgml1) and trypsin (0.2mgml1) for
6 hours at 37 1C. Cells were pelleted and then cultured in tissue
culture flasks. Isolated fibroblasts were cultured in low-glucose
DMEM supplemented with 10% FBS, 2mM L-glutamine, and
antibiotics. After reaching confluence, cells were treated with
0.05% trypsin (Gibco) and collected for subculturing. Cultured
fibroblasts that had been passaged less than eight times were used for
all the experiments. All studies strictly adhered to the guidelines of
the Institutional Review Board of Korea University. This study was
conducted according to the Declaration of Helsinki Principles.
In vitro scratch-wound-closure assays
In vitro scratch-wound-closure assays were performed as previously
described (Hu and Verkman, 2006). Cells were seeded into six-well
dishes at a density of 7 105 cells per well. The dishes were
cultured as confluent monolayers, synchronized in low-glucose
DMEM containing 10% FBS for 2 hours, and wounded by removing
a 300–500 mm-wide strip of cells across the well with a standard
200ml pipette tip. The wounded culture wells were washed twice
with PBS to remove non-adherent cells, and treated with various
inhibitors. Wound-closure effects were observed at least 24 hours
later.
In vitro proliferation and low-density seeding assay
Cell growth was determined by plating cells at a density of 2 104
(proliferation assay) or 102 cells per well (low density seeding assay)
in six-well plates and synchronizing them in low-glucose DMEM
containing 10% FBS. The inhibitors U0126, LY294002, AG490,
cucurbitacin-I, and EGCG were added to triplicate wells 6 hours
after plating and cells were cultured for the indicated times. For the
low-density seeding assay, cells were cultured more than 2 weeks.
Cells were then fixed with 10% formalin and stained with 0.01%
crystal violet. Crystal violet from stained cells was extracted using
10% acetic acid and quantified spectrophotometrically (600 nm) to
determine relative cell growth rates.
Senescence-associated b-galactosidase staining
Cell senescence was measured by senescence-associated b-galacto-
sidase staining (You et al., 2004). Briefly, cells were grown in 60-mm
cell culture dishes, washed three times with PBS, and fixed with 2%
formaldehyde/0.2% glutaraldehyde in PBS for 10minutes. The cells
were then washed and incubated with b-galactosidase substrate
solution (150mM NaCl, 2mM MgCl2, 5mM potassium ferricyanide,
5mM potassium ferrocyanide, 40mM citric acid, and 12mM sodium
phosphate, pH 6, containing 1mgml1 5-bromo-4-chloro-3-indolyl-
b-d-galactoside (X-gal)) for 24 hours at 37 1C.
Cell-cycle analysis by flow cytometry
For cell-cycle analysis, flow cytometry was performed as previously
described (Sah et al., 2004). Cells were seeded into 100-mm dishes
at a density of 7 105 cells per dish, allowed to attach overnight,
and then treated with various concentrations of EGCG in culture
medium for 48 hours. Cells were harvested with trypsin and washed
twice before fixing with methanol overnight. The cells were
incubated in propidium iodide for an additional 30minutes. The
labeled cells were analyzed by flow cytometry. Apoptosis was
quantified by measuring the sub-G1/S DNA content.
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TUNEL assay
Apoptotic cells were detected using the TACS-XL In situ Apoptosis
Detection kit according to the manufacturer’s instructions
(R&D System). Briefly, KFs were seeded in six-well plates at a
density of 104 cells per well and then incubated with varying
doses of EGCG. After the indicated times, cells were fixed
and treated with proteinase-K for permeabilization. The apoptotic
DNA fragments were labeled with biotinylated nucleotides
using terminal deoxynucleotidyl transferase. The biotinylated
nucleotides were then detected using a streptavidin–horseradish
peroxidase conjugate and diaminobenzidine. The numbers of
TUNEL-positive cells were counted, and at least 10,000 cells in
five randomly selected microscopic fields were scored for each
group (n¼ 3).
Semi-quantitative reverse transcription-PCR
Total RNA was prepared using Trizol reagent (Invitrogen, Carlsbad,
CA). Standard reverse transcription was performed using 500 ng of
total RNA, an oligo-d(T)1218 primer (Gibco), and superscriptase II
(Invitrogen). Reverse transcription-PCR used 1ml of cDNA template,
10 pmol of primers, and a PCR premix (1U Taq DNA polymerase,
250mM dNTPs, 10mM Tris-HCl, 40mM KCl and 1.5mM MgCl2;
Bioneer, Seoul, Korea). PCR analysis was performed using the follow-
ing primers: c-Myc, 50-TCGGATTCTCTGCTCTCCTC-30, 50-CGCCTCT
TGACATTCTCCTC-30; cyclin-D, 50-CAAATGTGTGCAGAAGGAGG-30,
50-CTGGCATTTTGGAGAGGAAG-30; collagen type-I a1-chain, 50-C
ACAGAGGTTTCAGTGGTTTGG-30, 50-GCACCAGTAGCACCATCA
TTTC-30; VEGF, 5-GAAACCATGAACTTTCTGCTG-3, 5-TCCTTCCT
CTGCCCGGCTA-3; glycerladehyde-3-phosphate dehydrogenase,
50-GTGGTCTCCTCTGACTTCAACA-30, 50-CTCTTCCTCTTGTGCTC
TTGCT-30. All primer pairs had a calculated annealing temperature
of 62 1C. PCR was conducted using GeneAmp 9600 (Perkin Elmer,
Boston, MA) with a 5-minute denaturation step at 94 1C, 30 cycles of
94 1C for 30 seconds, 62 1C for 30 seconds, and 72 1C for 30 seconds,
and a final extension for 10minutes at 72 1C. PCR amplifications
were verified to be in the linear range.
Western blot analysis
To detect protein expression and modification in response to
treatment with U0126, LY294002, AG490 and EGCG, cells plated
at a density of 5 105 cells per dish were cultured for the indicated
times (1.5 hours or 2 days) in growth medium in the presence or
absence of inhibitors. Total protein was extracted with radio-
immunoprecipitation assay buffer (50mM Tris-HCl pH 7.5, 150mM
NaCl, 1% Nonidet-40 (NP-40), 0.5% sodium deoxycholate, 1%
SDS, 1mM sodium orthovanadate, 1mM b-glycerol phosphate, 1mM
sodium fluoride, 2.5mM sodium pyrophosphate) containing a
protease inhibitor cocktail (Roche, Nutley, NJ). Lysates were centri-
fuged at 12,000 g for 30minutes at 4 1C. Protein concentrations were
determined using the Bradford assay kit (BioRad, Hercules, CA).
Protein (50 mg) was separated using precast 4–12% gradient SDS-
PAGE (Invitrogen) and transferred onto polyvinylidene difluoride
membranes (Invitrogen). Blots were incubated with the indicated
primary antibodies and horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit secondary antibodies (1:2,000 dilution). All of
the primary antibodies were used at a final concentration of
1mgml1. Blots were then visualized using a chemiluminescence
detection system as recommended by the manufacturer (Pierce).
For detecting collagen expression in cell culture supernatants,
2-day-cultured conditioned media were collected, concentrated
10 times with Centricon Centrifugal Filter (30-kDa cut-off) and
blotted described above.
siRNA transfection
Cells were treated with an siRNA for either 48 or 72 hours. Cells
were transfected with siRNA overnight with Oligofectamine
(Invitrogen) in Opti-MEM (Invitrogen) and supplemented with 10%
FBS the next morning. The concentration of siRNA was 3mmol per
100-mm dish. For complete inhibition of STAT3, all STAT3 siRNAs
(STAT3 siRNAs 1–3) were co-transfected at the concentration of
2mmol per 100-mm dish of each STAT3 siRNAs. STAT3 siRNAs 1–3
were purchased from Bioneer. Cells were assayed by western
blotting and in vitro wound-closure assay 48 hours after transfection.
Implantation of cultured human fibroblasts into nude mice
and EGCG treatment
We tested the therapeutic potential of EGCG in treatment of keloids
using an in vivo model (Fujiwara et al., 2005; Zhu et al., 2007).
Briefly, keloid and NFs were implanted into the dorsal area of BALB/
c nude mice weighing 18–22 g (Central Lab. Animal Inc., Seoul,
Korea). Fibroblasts (5 108 cells per injection) were injected into the
panniculus muscle using a syringe with a 26-gauge needle (Korea
Vaccine Co. Ltd, Seoul, Korea). At 7 days post implantation, mice
were randomly grouped and given intra-lesion injections of 1.5mg
per nodule of EGCG or the vehicle (PBS). At 17 days post
implantation, all animals were killed and keloid nodules were
excised and weighed. The nodule growth ratio was calculated as
follows:
Inhibition ratio ð%Þ ¼ ½ðC TÞ=C100%
where C represents the average nodule weight of the control group
and T is the average nodule weight of EGCG-treated mice. Some
nodule tissues were fixed in formaldehyde for immunohistochemical
analysis. All studies were conducted in strict adherence to the
guidelines of the Institutional Review Board of Korea University.
Hematoxylin and eosin staining
Normal and keloid nodules were fixed with 4% paraformaldehyde in
PBS, embedded in paraffin, and sectioned. Tissue sections were
stained with hematoxylin for 5–8minutes, washed with running
water, quickly destained with acid ethanol containing 1% hydro-
chloric acid and 70% ethanol, washed with running water, and
counterstained with eosin–ethanol for 3–5minutes. Tissue sections
were then rehydrated by gradual immersion in 70, 80, 95, and 100%
ethanol, cleared with xylene, and finally mounted in entellan.
Immunohistochemistry
Normal and keloid nodules after formaldehyde fixation and paraffin
embedding was cut into three fragments with 5B6mm thickness. It is
then washed with xylene to remove paraffin and immunohisto-
chemical staining was performed on each fragment for human
collagen, and p-Tyr705 STAT3. To maintain antigenicity of protein,
the microwave oven method was used to treat it in boiling PBS, and
hydrogen peroxide was applied to inhibit any activation of intrinsic
peroxidase. After that, primary antibodies against human collagen
and p-Tyr705 STAT3, which were diluted at a 1:100 ratio, were
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induced to show reactions at room temperature for 2 hours. The
secondary FITC or Cy3-labeled antibodies (LSAB kit; Dako, Glastrup,
Denmark) was induced to show reaction for 20minutes and then
washed in PBS. Sections were washed again and mounted with
Vectashield mounting medium containing 4,6-diamidino-2-pheny-
lindole (DAPI). Picture was taken with Olympus DP 70 Digital
Camera System. (Olympus, Tokyo, Japan).
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SUPPLEMENTARY MATERIAL
Figure S1. EGCG does not induce apoptosis.
Figure S2. EGCG has a stronger inhibitory effect on KF proliferation and
migration than dexamethasone.
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